ALG-902

ALG-902 is an early-stage investigational therapeutic candidate being developed by AliveGen for the treatment of cardiopulmonary diseases. Currently in the discovery phase, the drug is part of AliveGen's pipeline of next-generation protein-based therapeutics. AliveGen utilizes a proprietary protein engineering platform to design molecules that modulate signaling pathways within the TGF-beta superfamily, which are implicated in muscle wasting, metabolic disorders, and fibrotic conditions. While the specific molecular target and mechanism of action for ALG-902 have not been publicly disclosed, the program represents the company's expansion into cardiopulmonary indications using its engineered ligand trap and fusion protein technology.